Pathalys Pharma's Pivotal Phase 3 Study Findings to be Highlighted at ASN Kidney Week 2026

Pathalys Pharma to Present at ASN Kidney Week 2026

Raleigh, N.C. – Pathalys Pharma, Inc., a dedicated biopharmaceutical firm focused on the needs of chronic kidney disease (CKD) patients, has announced an important development in its research journey. The company will showcase ground-breaking data from its Phase 3 studies on upacicalcet, an investigational drug targeting secondary hyperparathyroidism (SHPT) at the ASN Kidney Week 2026, set to take place in Denver, Colorado, from October 21 to 25, 2026.

SHPT is a frequent complication among patients suffering from end-stage kidney disease who are undergoing hemodialysis, affecting nearly all individuals in this patient group. Despite improvements in treatment, many gaps in managing SHPT remain. The findings from Pathalys’s recent trials are set to address these issues head-on, with an emphasis on enhancing patient care and clinical outcomes.

The data will be presented in a special late-breaking oral presentation scheduled for October 23, 2026, from 4:30 PM to 6:00 PM MDT. Dr. Jessica B. Kendrick, the presenting author, will deliver insights regarding the efficacy and safety of upacicalcet based on two randomized controlled trials known as PATH-1 and PATH-2. These trials were designed to evaluate upacicalcet's effectiveness in SHPT management among patients on maintenance dialysis.

In addition to the oral presentation, there will be a poster presentation detailing biomarker results from the trials, contributing further to the understanding of CKD-MBD dynamics. This session is titled “CKD-MBD Biomarker Profile in Patients on Hemodialysis with Secondary Hyperparathyroidism Treated with Upacicalcet” and will occur on the same day from 10:00 AM to 12:00 PM MDT.

Neal Fowler, CEO of Pathalys Pharma, expressed the significance of these presentations, stating, “Addressing the troubles that accompany SHPT is not merely a goal for us but a vital mission. Presenting our findings at such a prestigious event underscores our dedication to advancing treatment innovations for patients and healthcare providers engaged in managing chronic kidney disease.”

Established in 2021, Pathalys Pharma has been at the forefront of developing targeted therapies for conditions associated with CKD. Upacicalcet is an investigational small molecule designed to optimize the management of SHPT by acting as a calcimimetic, effectively improving calcium and parathyroid hormone levels in patients.

With approximately 486,000 patients undergoing hemodialysis annually in the U.S. affected by CKD, Pathalys’s research signifies a hopeful shift in how SHPT can be treated and managed.

For those attending ASN Kidney Week 2026, this presentation promises to deliver valuable insights into the ongoing challenges and innovative solutions in the realm of nephrology and CKD management.

Learn more about Pathalys Pharma and their commitment to CKD treatment at PATHALYS.com. Be sure to follow their journey and stay updated through their LinkedIn page.